GLP-1 and Extra-islet Effects

 

 Buy Article Permissions and Reprints

Abstract

The main target of action of glucagon-like peptide-1 (GLP-1) is the islet, where the hormone stimulates insulin secretion, promotes beta cell proliferation and neogenesis, and inhibits glucagon secretion. However, GLP-1 receptors are also expressed outside the islets, increasing the likelihood that GLP-1 also plays a role in other organs. These functions are mainly the inhibition of gastric emptying, gastric acid secretion and exocrine pancreatic secretion, indicating that the hormone acts as an enterogastrone - a hormone released from the distal portion of the small intestine that inhibits proximal gastrointestinal events. Another important action of GLP-1 is to induce satiety. Other effects of the hormone include cardioprotection, neuroprotection, induction of learning and memory, stimulation of afferent, sensory nerves, stimulation of surfactant production in the lung, dilatation of pulmonary vessels, induction of diuresis, and also under some conditions, induction of antidiabetic actions unrelated to islet function. Thus, GLP-1 clearly has several manifestations of activity. The physiological relevance of these actions and their contribution to the overall antidiabetic action of GLP-1 when used in treatment of type 2 diabetes remains to be established.

References

• 1 Holz G G. Beta cell signaling of GLP-1.  Horm Metab Res. 2004;  36 786-794
  PubMedGoogle Scholar
• 2 Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells.  Horm Metab Res. 2004;  36 822-829
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Rorsman P, Gromada J. GLP-1 and alpha-cell effects.  Horm Metab Res. 2004;  in press
  PubMedGoogle Scholar
• 4 Brubaker P L, Drucker D J. Structure - function of the glucagon receptor family of G protein-cupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.  Receptors Channels. 2002;  8 179-188
  CrossrefPubMedGoogle Scholar
• 5 Larsen P J, Tang-Christensen M, Holst J J, Ørskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.  Neuroscience. 1997;  77 257-370
  CrossrefPubMedGoogle Scholar
• 6 Shimizu I, Hirota M, Ohjboshi C, Shima K. Identification and localization of glucagon-like peptide 1 and its receptor in rat brain.  Endocrinology. 1987;  121 1076-1082
  PubMedGoogle Scholar
• 7 Uttenthal L O, Toledano A, Blasquez E. Autoradiographuc localization of receptors for glucagon-like peptide-1 (7 - 36)amide in rat brain.  Neuropeptides. 1992;  21 143-146
  CrossrefPubMedGoogle Scholar
• 8 Fehmann H C, Göke R, Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide.  Endocr Rev. 1995;  16 390-4010
  CrossrefPubMedGoogle Scholar
• 9 Bullock B P, Heller R S, Habener J F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor.  Endocrinology. 1996;  137 2968-2978
  CrossrefPubMedGoogle Scholar
• 10 Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences.  FEBS Lett. 1995;  358 219-224
  CrossrefPubMedGoogle Scholar
• 11 Alvarez E, Roncero J, Chowen J A, Thorens B, Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain.  J Neurochem. 1996;  66 920-927
  PubMedGoogle Scholar
• 12 Merchenthaler I, Lane M, Shughrue P. Distribution of the preproglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.  J Comp Neurol. 1999;  403 261-280
  PubMedGoogle Scholar
• 13 Valverde I, Morales M, Clemente F, Lopez-Delgado M I, Delgado E, Perea A, Villanueva-Penacarrillo M L. Glucagon-like peptide 1: a potent glycogenic hormone.  FEBS Lett. 1994;  349 313-316
  CrossrefPubMedGoogle Scholar
• 14 Villanueva-Penacarillo M L, Alcanatara A I, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7 - 36) amide in rat skeletal muscle.  Diabetologia. 1994;  37 1163-1166
  PubMedGoogle Scholar
• 15 Galera C, Clemente F, Alcanatara A, Trapote M A, Perea A, Lopez-Delgado M I, Villanyeva-Penecarrillo M L, Valverde I. Inositolphosphoglycans and diacylglycerol are possible mediators in the glycogenic effect of GLP-1(7 - 36)amide in BC3H-1 myocytes.  Cell Biochem Funct. 1996;  14 43-48
  PubMedGoogle Scholar
• 16 Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose M H, Adams L G. Novel signal transduction and peptide specificity of glucagon-like peptide receptors in 3T3-LI adipocytes.  J Cell Physiol. 1997;  172 275-283
  CrossrefPubMedGoogle Scholar
• 17 Wheeler M B, Lu M, Dillon J S, Leng X H, Chen C, Boyd III A E. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase C.  Endocrinology. 1993;  133 57-62
  CrossrefPubMedGoogle Scholar
• 18 Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1.  Am J Physiol. 1996;  271 E808-E813
  PubMedGoogle Scholar
• 19 Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.  J Autonom Nerv Syst. 2000;  80 14-21
  CrossrefPubMedGoogle Scholar
• 20 Dhillo W S, Bloom S R. Gastrointestinal hormones and regulation of food intake.  Horm Metab Res. 2004;  36 846-851
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Rizza R A. Extrapancreatic effects of GIP and GLP-1.  Horm Metab Res. 2004;  36 830-836
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Kosaka T, Lim R KS. Demonstration of the humoral agent in fat inhibition on gastric secretion.  Proc Soc Exp Biol Med. 1930;  27 890-891
  PubMedGoogle Scholar
• 23 Näslund E, King N, Mansten S, Adner N, Holst J J, Gutniak M, Hellström P M. Prandial subcutaneous injections of glucagon-like peptide-I cause weight loss in obese human subjects.  Br J. Nutr. 2004;  91 439-446
  CrossrefPubMedGoogle Scholar
• 24 Nauck M A, Niedereichholz U, Ettler R, Holst J J, Ørskov C, Ritzel R, Schmiegel W H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.  Am J Physiol. 1997;  273 E981-E988
  PubMedGoogle Scholar
• 25 Gutniak M K, Svartberg J, Hellström P M, Holst J J, Adner N, Ahrén B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.  Int J Med. 2001;  250 81-87
  PubMedGoogle Scholar
• 26 Wettergren A, Wøjdemann M, Holst J J. Glucagon-like peptide-1 (GLP-1) inhibits gastropancreatic function by inhibiting central parasympathetic outflow.  Am J Physiol. 1998;  275 G984-G992
  PubMedGoogle Scholar
• 27 Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst J J. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7 - 36 amide on gastric acid secretion in humans depends on an intact vagal innervation.  Gut. 1997;  40 597-601
  PubMedGoogle Scholar
• 28 Näslund E, Gutniak M, Skogar S, Rössner S, Hellström P M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.  Am J Clin Nutr. 1998;  68 525-530
  PubMedGoogle Scholar
• 29 Flint A, Raben A, Ersbøll A K, Holst J J, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.  Int J Obes. 2001;  25 781-792
  PubMedGoogle Scholar
• 30 Kolterman O G, Buse J B, Fineman M S, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron A D. Synthetic edenxin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.  J Clin Endocrinol Metab. 2003;  88 3082-3089
  CrossrefPubMedGoogle Scholar
• 31 Holst J J. Enteroglucagon.  Ann Rev Physiol. 1997;  59 257-271
  CrossrefPubMedGoogle Scholar
• 32 Barragan J M, Rodriguez R E, Blazguez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7 - 36) amide in rats.  Am J Physiol. 1994;  266 E459-E466
  PubMedGoogle Scholar
• 33 Yamamoto H, Lee C E, Marcus J N, Williams T D, Overton J M, Lopez M E, Hollenberg A N, Baggio L, Saper C B, Brucker D J, Elmquist J K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.  J Clin Invest. 2002;  110 43-52
  CrossrefPubMedGoogle Scholar
• 34 Barragan J M, Rodriguez R E, Eng J, Blazquez E. Interactions of exendin-(9 - 39) with the effects of glucagon-like peptide-1-(7 - 36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.  Regul Pept. 1996;  67 63-68
  CrossrefPubMedGoogle Scholar
• 35 Gros R, You X, Baggio L L, Kabir M G, Sadi A M, Mungrue I N, Parker T G, Huang Q, Drucker D J, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor.  Endocrinology. 2003;  144 2242
  CrossrefPubMedGoogle Scholar
• 36 Bose A K, Mocanu M M, Mensah K N, Brand C L, Carr R D, Yellon D M. GLP-1 protects ischemic and reperfused myocardium via PI3kinase and p42/p44-MAPK signaling pathways.  Diabetes. 2004;  53 Suppl 2 A1 (2004)
  PubMedGoogle Scholar
• 37 Imeryoz N, Yegen B C, Bozkurt A, Coskun T, Villanueva-Penecarrillo M L, Ulusoy N B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.  Am J Physiol. 1997;  273 G920-G927
  PubMedGoogle Scholar
• 38 Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms.  Am J Physiol. 2000;  279 R1449-R1454
  PubMedGoogle Scholar
• 39 Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 (GLP-1) in mice.  Am J Physiol. 2004;  286 R269-R272
  PubMedGoogle Scholar
• 40 Burcelin R, da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.  Diabetes. 2001;  50 1720-1728
  PubMedGoogle Scholar
• 41 Ahrén B, Larsson H, Holst J J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in non-insulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1997;  82 473-478
  CrossrefPubMedGoogle Scholar
• 42 D'Alessio D A, Kahn S E, Leusner C R, Ensinck J W. Glucagon-like peptide I enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.  J Clin Invest. 1994;  93 2263-2266
  PubMedGoogle Scholar
• 43 Ørskov L, Holst J J, Moller N, Alberti K GMM, Schmitz O. GLP-1 does not acutely affect insulin in healthy men.  Diabetologia. 1996;  39 1227-1232
  PubMedGoogle Scholar
• 44 Toft-Nielsen M, Madsbad S, Holst J J. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.  Diabetes. 1996;  45 552-556
  PubMedGoogle Scholar
• 45 Egan J M, Meneilly G S, Habener J F, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.  J Clin Endocrinol Metab. 2002;  87 3768-3773
  CrossrefPubMedGoogle Scholar
• 46 Meneilly G S, McIntosh C H, Pederson R A, Habener J F, Gingerich R, Egan J M, Elahi D. Glucagon-like peptide-1 (7 - 37) augments insulin-mediated glucose uptake in elderly patients with diabetes.  J Gerontol A Biol Sci Med Sci. 2001;  56 M681-M685
  PubMedGoogle Scholar
• 47 Zander M, Madsbad S, Lysgaard Madsen J, Holst J J. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.  Lancet. 2002;  359 824-830
  CrossrefPubMedGoogle Scholar
• 48 Larsson H, Holst J J, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans.  Acta Physiol Scand. 1997;  160 413-422
  CrossrefPubMedGoogle Scholar
• 49 Nishizawa M, Moore M, Shiota M, Gustavson S, Snead W, Neal D, Cherrington A. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.  Am J Physiol. 2003;  284 E1027-E1036
  PubMedGoogle Scholar
• 50 Prigeon R L, Quddusi S, Paty B, D'Alessio D A. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: a novel extrapancreatic effect.  Am J Physiol. 2003;  285 E701-E707
  PubMedGoogle Scholar
• 51 Yu M, Moreno C, Hoagland K M, Dahly A, Ditter K, Mistry M, Roman R J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.  J Hyperten. 2003;  21 1125-1135
  CrossrefPubMedGoogle Scholar
• 52 Gutzwille J P, Tschopp S, Bock A, Zehnder C E, Huber A R, Kreuenbuehl M, Gutmann H, Drewe J, Henzen C, Göke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.  J Clin Endocrinol Metab. 2004;  89(6) 3055-3061
  CrossrefPubMedGoogle Scholar
• 53 Golpon H A, Puechner A, Welte T, Wichert P V, Feddersen C O. Vasorelaxant effect of glucagon-like peptide-(7 - 36)amide4 and amylin in the pulmonary circulation of the rat.  Regul Pept. 2001;  102 81-86
  CrossrefPubMedGoogle Scholar
• 54 Benito E, Blazquez E, Bosch M A. Glucagon-like peptide-1-(7 - 36) amide increases pulmonary surfactant secretion through a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes.  Endocrinology. 1998;  139 2363-2368
  CrossrefPubMedGoogle Scholar
• 55 Vara E, Arias-Diaz J, Garcia C, Balibrea J L, Blazquez E. Glucagon-like peptide-1(7 - 36)amide stimulates surfactant secretion in human type II pneumocytes.  Am J Respir Crit Care Med. 2001;  163 840-846
  PubMedGoogle Scholar

Dr B. Ahrén

Department of Medicine

B11 BMC · SE-221 84 Lund · Sweden

Phone: +46462220758 ·

Fax: +46462220757

Email: Bo.Ahren@med.lu.se